14 registrations that name eloralintide as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 14 registrations
Status
Phase
397US sites across 37 states
1
2 to 4
5 to 19
20 or more
All 14 registrations
RecruitingNCT07282600
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Phase 3
Eli Lilly and Company
About 1,035 people
Started Dec 15, 2025
In plain words A Phase 3 study of eloralintide in people 18 and older, run by Eli Lilly and Company. It plans to enroll about 1,035 people at 143 sites, 60 of them in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Overweight; Obesity.
Have type 2 diabetes
Are on stable treatment for type 2 diabetes for at least 90 days prior to screening
Have a BMI ≥ 27 kg/m2
Have a stable body weight (<5% body weight change) for 90 days prior to screening
The exclusion criteria are on the listing.
What it tests, as registered
Eloralintide; Placebo
Registered summary
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.
Where, as registered
60 US sites in 25 states; also China (16), Japan (15), Spain (9), Poland (8), Germany (7), Slovakia (6), Mexico (5), South Korea (5), Taiwan (5), Czechia (4), Puerto Rico (2), India (1).
RecruitingNCT07392190
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
Phase 3
Eli Lilly and Company
About 900 people
Started Feb 10, 2026
In plain words A Phase 3 study of eloralintide in people 18 and older, run by Eli Lilly and Company. It plans to enroll about 900 people at 185 sites, 59 of them in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Overweight; Obesity.
Are on stable incretin therapy at screening
With persistent obesity or overweight defined as:
≥30 kg/m2 OR
≥27 kg/m2 with at least one existing obesity related complication at screening:
6 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Eloralintide; Placebo
Registered summary
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy. Participation in the study will last about 80 weeks.
Where, as registered
59 US sites in 22 states; also China (22), Israel (17), Japan (11), Australia (10), India (10), Romania (10), Spain (10), Belgium (9), Taiwan (9), Brazil (7), Mexico (6), Czechia (3), Puerto Rico (2).
RecruitingNCT06143956
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Phase 2
Eli Lilly and Company
About 1,481 people
Started Nov 17, 2023
In plain words A Phase 2 study of eloralintide in people 18 to 75, run by Eli Lilly and Company. It plans to enroll about 1,481 people at 57 sites, 50 of them in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: Obesity; Overweight.
Have a body mass index (BMI)
≥30 kilogram/square meter (kg/m²), or
≥27 kg/m² and <30 kg/m², or with at least 1 weight-related comorbidity
Have had a stable body weight for the 3 months prior to randomization (<5%) body weight gain and/or loss.
The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newly enrolled participants across the master and the ISAs. The ISAs may start independently of other ISAs as interventions become available for clinical testing. The results for the CWMM screening record will be reported when all the ISA's complete.
Where, as registered
50 US sites in 22 states; also Argentina (7).
RecruitingNCT07321886
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
Phase 3
Eli Lilly and Company
About 1,980 people
Started Feb 6, 2026
In plain words A Phase 3 study of eloralintide in people 18 and older, run by Eli Lilly and Company. It plans to enroll about 1,980 people at 158 sites, 41 of them in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Obesity; Overweight.
Have Body Mass Index (BMI) at screening of the following:
30 kilogram per square meter (kg/m2) OR
27 kg/m2 with at least one of the following weight-related health conditions at screening:
high blood pressure
5 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Eloralintide; Placebo
Registered summary
The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase. Participation in the main phase of the study will last about 75 weeks. Participants with prediabetes will continue in the extension phase for another 2 years.
Where, as registered
41 US sites in 23 states; also China (14), Germany (12), Australia (11), Argentina (10), India (10), Canada (9), Japan (9), Poland (9), United Kingdom (9), Brazil (8), South Korea (5), Taiwan (5), Belgium (4), Puerto Rico (2).
RecruitingNCT07589608
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
Phase 2
Eli Lilly and Company
About 400 people
Started May 15, 2026
In plain words A Phase 2 study of eloralintide in people 18 to 75, run by Eli Lilly and Company. It plans to enroll about 400 people at 40 US sites.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: Overweight; Obesity.
See Master Protocol CWMM (NCT06143956) for inclusion criteria
The exclusion criteria are on the listing.
What it tests, as registered
Macupatide; Eloralintide; Placebo
Registered summary
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will last about 64 weeks.
Where, as registered
40 US sites in 20 states.
RecruitingNCT07353931
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
Phase 3
Eli Lilly and Company
About 900 people
Started Feb 9, 2026
In plain words A Phase 3 study of eloralintide in people 18 and older, run by Eli Lilly and Company. It plans to enroll about 900 people at 153 sites, 39 of them in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Osteoarthritis; Overweight or Obesity.
Have a body mass index (BMI) of 27 kilograms per square meter (kg/m²) or higher at screening
Have a stable body weight (less than 5% body weight change) for 90 days prior to screening
Have tried at least once to lose weight through diet but were unsuccessful
Have osteoarthritis of the knee and at least one of the following conditions:
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Eloralintide; Placebo
Registered summary
The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 75 weeks, including screening.
Where, as registered
39 US sites in 19 states; also China (23), Japan (15), Argentina (14), Belgium (8), Germany (8), South Korea (8), United Kingdom (8), Canada (7), Taiwan (7), Brazil (6), Czechia (5), Denmark (3), Puerto Rico (2).
RecruitingNCT07369011
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Phase 3
Eli Lilly and Company
About 800 people
Started Feb 10, 2026
In plain words A Phase 3 study of eloralintide in people 18 and older, run by Eli Lilly and Company. It plans to enroll about 800 people at 115 sites, 23 of them in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Sleep Apnea, Obstructive; Obesity; Overweight.
Confirmed history of moderate-to-severe OSA
Have an AHI ≥ 15 on polysomnography (PSG) as part of the study at screening
Have a BMI ≥27 kg/m2 at screening
Have a stable body weight (<5% body weight change) for 90 days prior to screening
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Eloralintide; Placebo
Registered summary
The purpose of the studies is to evaluate the efficacy and safety of eloralintide in participants with moderate-to-severe obstructive sleep apnea and obesity or overweight. YDAO is a master protocol designed to support two independent studies: YSA1 and YSA2. Study YSA1 will include participants who are unable or unwilling to use Positive Airway Pressure (PAP) therapy and study YSA2 will include participants who are on PAP therapy for at least 3 months at time of screening and plan to continue PAP therapy during the study. The full summary is on the listing.
Where, as registered
23 US sites in 16 states; also China (22), India (12), Brazil (10), Japan (10), Spain (9), Australia (8), Germany (8), Canada (6), South Korea (4), Taiwan (3).
RecruitingNCT07401862
A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.
Phase 1
Eli Lilly and Company
About 36 people
Started Feb 10, 2026
In plain words A Phase 1 study of eloralintide in people 18 to 85, run by Eli Lilly and Company. It plans to enroll about 36 people at 3 sites, 2 of them in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 85; healthy volunteers accepted. Conditions: Hepatic Insufficiency.
Have a body weight of 55 kilograms (kg) or more and body mass index between 19.0 and 40.0 kilograms per square meter (kg/m²), inclusive
Are healthy as determined by medical history, physical examination, and other screening procedures, with clinically normal hepatic function at screening
Have hepatic impairment classified as Child-Pugh score A, B, or C (mild, moderate, or severe impairment who are considered acceptable for participation in this study by the investigator.
The exclusion criteria are on the listing.
What it tests, as registered
LY3841136
Registered summary
The main purpose of this study is to evaluate how a medicine, LY3841136, works in participants with different levels of liver damage and in participants with healthy liver. The researchers want to see how the medicine is absorbed and used by the body, and if it causes any side effects, in participants with mild, moderate, or severe liver damage, as well as in participants with normal liver function. For each participant, the study will last about 14 weeks, which will include a stay at the clinical research unit for 5 nights.
Where, as registered
2 US sites in 2 states; also Hungary (1).
RecruitingNCT07808060
A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight
Phase 1
Eli Lilly and Company
About 34 people
Started Sep 15, 2026
In plain words A Phase 1 study of eloralintide in female participants 18 to 60, run by Eli Lilly and Company. It plans to enroll about 34 people at 2 US sites.
Are individuals AFAB who are individuals of childbearing potential using non-hormonal methods of contraception, or individuals not of childbearing potential.
Have safety laboratory test results within normal reference range for the population or investigative site.
Have a body mass index (BMI) within the range of 27.0 to 35.0 kilograms per square meter (kg/m²), inclusive.
Have had a stable body weight, with less than 5 percent (%) change during the 3-month period prior to screening.
The exclusion criteria are on the listing.
What it tests, as registered
Eloralintide; Combined oral contraceptive
Registered summary
The main purpose of this study is to evaluate how eloralintide (LY3841136) effects the way the body processes oral contraceptive in female participants with obesity or overweight. For each participant, the study will last about 8 months and will include 3 stays in the Clinical Research Unit (CRU), each lasting between 6 - 8 nights.
Where, as registered
2 US sites in 2 states.
RecruitingNCT07738614
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight
Phase 1
Eli Lilly and Company
About 56 people
Started Jul 31, 2026
In plain words A Phase 1 study of eloralintide in people 18 to 65, run by Eli Lilly and Company. It plans to enroll about 56 people at 2 sites, 1 of them in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65; healthy volunteers accepted. Conditions: Obesity; Overweight.
Have overweight or obesity, but are otherwise overtly healthy.
Have a body mass index (BMI) within the range of 27.0 to 45.0 kilograms (kg)/square meter (m²), inclusive.
Have had a stable body weight, with less than 5 percent (%) change during the 3-month period prior to screening.
The exclusion criteria are on the listing.
What it tests, as registered
Eloralintide; Placebo; Acetaminophen
Registered summary
The main purpose of this study is to find out how significantly Eloralintide slows stomach emptying in participants who are overweight or obese. For each participant, the study will last approximately 21 weeks and will include 2 overnight stays in the clinical research unit (CRU) lasting between 4 and 8 days. There will be 13 other visits.
Where, as registered
1 US site in 1 state; also Singapore (1).
RecruitingNCT07665879
A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity
Phase 1
Eli Lilly and Company
About 115 people
Started Jun 24, 2026
In plain words A Phase 1 study of eloralintide in people 18 to 70, run by Eli Lilly and Company. It plans to enroll about 115 people at 2 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 70; healthy volunteers accepted. Conditions: Overweight; Obesity.
Have an hemoglobin A1c (HbA1c) value at screening of less than 6.5 percent (%).
Have a body mass index between 25 and 45 Kilogram per Square Meter (kg/m²).
Have had a stable body weight that has changed by less than 5% during the 3 months prior to screening.
Are individuals assigned male at birth (AMAB) or assigned female at birth (AFAB). Individuals of childbearing potential (IOCBP) and individuals not of childbearing potential (INOCBP) may participate in this study.
The exclusion criteria are on the listing.
What it tests, as registered
Eloralintide; Placebo
Registered summary
The main purpose of the study is to measure and compare the effects of eloralintide and placebo on insulin sensitivity (how your body responds to insulin), metabolic health (things like sugar and cholesterol), and body weight in participants with obesity or overweight. For each participant, the study will last about 35 weeks and include 3 in patient visits totaling 7 days.
Where, as registered
No US site; Germany (1), Sweden (1).
Not yet recruitingNCT07881432
A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes
Phase 3
Eli Lilly and Company
About 2,115 people
Starts Dec 2026 (estimated)
In plain words A Phase 3 study of eloralintide in people 18 and older, run by Eli Lilly and Company. It plans to enroll about 2,115 people at 155 sites, 55 of them in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Obesity.
Have a stable self-reported body weight (<5% body weight change) for 90 days prior to screening
Have a BMI of ≥35 kg/m2 at screening
Have a history of at least 1 self-reported unsuccessful dietary effort to reduce body weight
The exclusion criteria are on the listing.
What it tests, as registered
eloralintide and tirzepatide; Eloralintide; Tirzepatide; Placebo
Registered summary
The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared with tirzepatide, eloralintide and placebo for body weight reduction in participants with obesity. Participation in the study will last about 2 years.
Where, as registered
55 US sites in 21 states; also China (25), Argentina (20), South Korea (13), India (12), Germany (11), Japan (10), United Kingdom (6), Puerto Rico (3).
Not yet recruitingNCT07881458
A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Phase 3
Eli Lilly and Company
About 1,000 people
Starts Nov 2026 (estimated)
In plain words A Phase 3 study of eloralintide in people 18 and older, run by Eli Lilly and Company. It plans to enroll about 1,000 people at 75 sites, 25 of them in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Obesity; Overweight; Diabetes Mellitus, Type 2.
Have type 2 diabetes
Have a stable self-reported body weight (<5% body weight change) for 90 days prior to screening
Have a BMI of ≥27 kg/m2 at screening
Have a history of at least 1 self-reported unsuccessful dietary effort to reduce body weight
The exclusion criteria are on the listing.
What it tests, as registered
eloralintide and tirzepatide; Tirzepatide
Registered summary
The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared to tirzepatide for body weight reduction in participants with obesity or overweight and type 2 diabetes. Participation in the study will last about 2 years.
Where, as registered
25 US sites in 14 states; also Romania (10), Spain (9), China (7), Brazil (6), Germany (6), Japan (5), South Korea (5), Puerto Rico (1), Taiwan (1).
Not yet recruitingNCT07765511
A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes
Phase 1
Eli Lilly and Company
About 60 people
Starts Oct 2026 (estimated)
In plain words A Phase 1 study of eloralintide in people 18 to 65, run by Eli Lilly and Company. It plans to enroll about 60 people at 3 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65; healthy volunteers accepted. Conditions: Obesity; Overweight.
Are Japanese participants assigned male at birth (AMAB) or assigned female at birth (AFAB) who agree to contraception requirements or participants who are individuals not of childbearing potential (INOCBP).
Have a body mass index greater than or equal to (≥)25 kilograms per square meter (kg/m²)
Have had a stable weight for the 3 months prior to screening. Stable weight is defined as less than 5 percent (%) body weight change.
The exclusion criteria are on the listing.
What it tests, as registered
Macupatide; Eloralintide; Placebo
Registered summary
The main purpose of this study is to assess how well macupatide, when dosed alone and in combination with eloralintide, is tolerated and what side effects may occur in participants with obesity or overweight without Type 2 diabetes. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. For each participant, the study will last about 4 months and will include 2 stays in the Clinical Research Unit (CRU), each lasting 3-5 nights.